Characterizing molecular and synaptic signatures in mouse models of late‐onset Alzheimer's disease independent of amyloid and tau pathology

Author:

Kotredes Kevin P.1,Pandey Ravi S.2,Persohn Scott34,Elderidge Kierra34,Burton Charles P34,Miner Ethan W.34,Haynes Kathryn A.5,Santos Diogo Francisco S.5,Williams Sean‐Paul5,Heaton Nicholas5,Ingraham Cynthia M.4,Lloyd Christopher4,Garceau Dylan1,O'Rourke Rita1,Herrick Sarah1,Rangel‐Barajas Claudia36,Maharjan Surendra347,Wang Nian347,Sasner Michael1,Lamb Bruce T.346,Territo Paul R.348,Sukoff Rizzo Stacey J.5,Carter Gregory W.12910,Howell Gareth R.1910,Oblak Adrian L.347

Affiliation:

1. The Jackson Laboratory Bar Harbor Maine USA

2. The Jackson Laboratory for Genomic Medicine Farmington Connecticut USA

3. Indiana University School of Medicine Indianapolis Indiana USA

4. Stark Neurosciences Research Institute Indianapolis Indiana USA

5. Department of Medicine University of Pittsburgh Aging Institute University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

6. Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA

7. Department of Radiology & Imaging Sciences Indiana University School of Medicine Indianapolis Indiana USA

8. Department of Medicine Division of Clinical Pharmacology Indiana University School of Medicine Indianapolis Indiana USA

9. Tufts University Graduate School of Biomedical Sciences Boston Massachusetts USA

10. Graduate School of Biomedical Sciences and Engineering University of Maine Orono Maine USA

Abstract

AbstractINTRODUCTIONMODEL‐AD (Model Organism Development and Evaluation for Late‐Onset Alzheimer's Disease) is creating and distributing novel mouse models with humanized, clinically relevant genetic risk factors to capture the trajectory and progression of late‐onset Alzheimer's disease (LOAD) more accurately.METHODSWe created the LOAD2 model by combining apolipoprotein E4 (APOE4), Trem2*R47H, and humanized amyloid‐beta (Aβ). Mice were subjected to a control diet or a high‐fat/high‐sugar diet (LOAD2+HFD). We assessed disease‐relevant outcome measures in plasma and brain including neuroinflammation, Aβ, neurodegeneration, neuroimaging, and multi‐omics.RESULTSBy 18 months, LOAD2+HFD mice exhibited sex‐specific neuron loss, elevated insoluble brain Aβ42, increased plasma neurofilament light chain (NfL), and altered gene/protein expression related to lipid metabolism and synaptic function. Imaging showed reductions in brain volume and neurovascular uncoupling. Deficits in acquiring touchscreen‐based cognitive tasks were observed.DISCUSSIONThe comprehensive characterization of LOAD2+HFD mice reveals that this model is important for preclinical studies seeking to understand disease trajectory and progression of LOAD prior to or independent of amyloid plaques and tau tangles.Highlights By 18 months, unlike control mice (e.g., LOAD2 mice fed a control diet, CD), LOAD2+HFD mice presented subtle but significant loss of neurons in the cortex, elevated levels of insoluble Ab42 in the brain, and increased plasma neurofilament light chain (NfL). Transcriptomics and proteomics showed changes in gene/proteins relating to a variety of disease‐relevant processes including lipid metabolism and synaptic function. In vivo imaging revealed an age‐dependent reduction in brain region volume (MRI) and neurovascular uncoupling (PET/CT). LOAD2+HFD mice also demonstrated deficits in acquisition of touchscreen‐based cognitive tasks.

Funder

National Institute on Aging

Translational Genomics Research Institute

National Institute of Neurological Disorders and Stroke

Mayo Foundation for Medical Education and Research

Arizona Department of Health Services

Arizona Biomedical Research Commission

Michael J. Fox Foundation for Parkinson's Research

Publisher

Wiley

Reference45 articles.

1. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective

2. Diet and Alzheimer’s disease risk factors or prevention: the current evidence

3. Biogen.FDA approves updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials.Biogen.2021. Available from:https://investors.biogen.com/news‐releases/news‐release‐details/fda‐approves‐updated‐aduhelmtm‐prescribing‐information‐emphasize

4. FDA.FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. FDA.2023. Available from:https://www.fda.gov/news‐events/press‐announcements/fda‐converts‐novel‐alzheimers‐disease‐treatment‐traditional‐approval

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3